Agios Pharma (AGIO) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Agios Reports Fourth Quarter and Full Year 2017 Financial Results
February 14, 2018 7:01 AM ESTAll 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios Discovery Platform and NDA Submission for Second Product Candidate, Ivosidenib, for IDH1m R/R AML
2018 Priorities Focus on Expanding Clinical and Research Programs to Drive Long-Term Value
 2017 Year-End Cash, Cash Equivalents and Marketable Securities was $568M; January Follow-on Offering of $516M Extends Cash Runway Through at Least the End of 2020
CAMBRIDGE, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the... More
